Authors: Alsina Maqueda M, Teijo Quintáns A, Cuatrecasas M, Fernández Aceñero MJ, Fernández Montes A, Gómez Martín C, Jiménez Fonseca P, Martínez Ciarpaglini C, Rivera Herrero F, Iglesias Coma M.
DOI: 10.1007/s12094-025-03865-6
Abstract Summary
New Spanish consensus guidelines identify four essential biomarkers (HER2, dMMR/MSI, PD-L1, Claudin18.2) for personalized gastroesophageal cancer treatment. With expanding therapeutic options beyond trastuzumab, immunohistochemistry-based biomarker testing is now crucial for optimizing targeted therapies in advanced disease.
Why Brain? 🧠
Spanish experts establish consensus on key biomarkers (HER2, dMMR/MSI, PD-L1, Claudin18.2) for personalized treatment of gastroesophageal cancers, optimizing targeted therapy selection in clinical practice.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
